Hi duke I agree with dx-1 being slim before ph 1 trials but...

Hi duke
I agree with dx-1 being slim before ph 1 trials but because of DX.3’s ability to hold more payload it is bringing in a lot more than just cancer scenarios

The conferance this week we are attending is for other measures besides cancer potential cancer cures, at least the timing is right for this if we can have a successful GMP

”non dilutive funding’ was from potential partners/deals the Dr was talking about a couple of years ago, we all know why this stalled, if back on track at least it will spark up more interest and debate about partners and jV’s ect and this is exactly what investors want as to revive traction/volume and above all sentiment again